Revance
Pre-clinicalDevelops neuromodulator products for aesthetic and therapeutic uses, including daxibotulinumtoxinA for injection.
Market Cap
Private
Pipeline
—
Patents
—
Publications
—
Private Company
Total funding raised: $433M
About
Develops neuromodulator products for aesthetic and therapeutic uses, including daxibotulinumtoxinA for injection.
AestheticsNeurology
Funding History
6Total raised:$433M
PIPE$150MSep 15, 2020
IPO$96MFeb 7, 2014
Series D$70MDec 15, 2011
Series C$52MMar 15, 2010